FGC
SKYE icon

Financial Gravity Companies’s Skye Bioscience SKYE Stock Holding History

Financial Gravity Companies’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$4.53K Hold
1,600
– – ﹤0.01% 684
2024
Q3 		$6.26K Buy
+1,600
New +$8.97K ﹤0.01% 417

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Financial Gravity Companies's SKYE Position: Q4 2024 in Review

Financial Gravity Companies held its Skye Bioscience (SKYE) position steady in Q4 2024 at 1,600 shares worth $4.53K. The position accounts for ﹤0.01% of the portfolio, ranked #684.

Financial Gravity Companies first reported a position in SKYE in Q3 2024 and has held it in 2 quarters since. The position peaked at $6.26K in Q3 2024. 73 funds tracked by Wall St. Rank hold SKYE as of Q4 2024.

  • Financial Gravity Companies held 1,600 shares of Skye Bioscience worth $4.53K as of Q4 2024.
  • Financial Gravity Companies left its Skye Bioscience share count unchanged in Q4 2024.
  • Skye Bioscience made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2024, its #684 holding.
  • Financial Gravity Companies first reported a position in Skye Bioscience in Q3 2024 and has held it in 2 quarters since.
  • Financial Gravity Companies's Skye Bioscience position peaked at $6.26K in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2024.

Based on Financial Gravity Companies's 13F filing for Q4 2024, filed 14 Feb 2025.